These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25261416)

  • 41. Apigenin as an anti-quinolone-resistance antibiotic.
    Morimoto Y; Baba T; Sasaki T; Hiramatsu K
    Int J Antimicrob Agents; 2015 Dec; 46(6):666-73. PubMed ID: 26526895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of quinolone-resistance acquisition on biofilm production and fitness in Salmonella enterica.
    Fàbrega A; Soto SM; Ballesté-Delpierre C; Fernández-Orth D; Jiménez de Anta MT; Vila J
    J Antimicrob Chemother; 2014 Jul; 69(7):1815-24. PubMed ID: 24706735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
    Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
    Huang X; Bao Y; Zhu S; Zhang X; Lan S; Wang T
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3928-32. PubMed ID: 26238324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A molecular analysis of quinolone-resistant Haemophilus influenzae: validation of the mutations in Quinolone Resistance-Determining Regions.
    Shoji H; Shirakura T; Fukuchi K; Takuma T; Hanaki H; Tanaka K; Niki Y
    J Infect Chemother; 2014 Apr; 20(4):250-5. PubMed ID: 24480551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai.
    Yang Y; Liao M; Gu WM; Bell K; Wu L; Eng NF; Zhang CG; Chen Y; Jolly AM; Dillon JA
    J Antimicrob Chemother; 2006 Oct; 58(4):868-72. PubMed ID: 16880174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An unusually high level of quinolone resistance associated with type II topoisomerase mutations in quinolone resistance-determining regions of Aeromonas caviae isolated from diarrhoeal patients.
    Sinha S; Chattopadhyay S; Bhattacharya SK; Nair GB; Ramamurthy T
    Res Microbiol; 2004 Dec; 155(10):827-9. PubMed ID: 15567276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    Int J Antimicrob Agents; 2020 Sep; 56(3):106082. PubMed ID: 32659467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
    Huband MD; Cohen MA; Zurack M; Hanna DL; Skerlos LA; Sulavik MC; Gibson GW; Gage JW; Ellsworth E; Stier MA; Gracheck SJ
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1191-201. PubMed ID: 17261623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.